Innovation and education in the pharmaceutical industry are significant areas of investment for the field’s future development. Biofrontera Inc., a pioneer in biopharma, is one of the top contributors to the advancement of modern global medicine.

Biofrontera Inc. is a U.S. based pharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Their flagship product is a drug product used in combination with their LED light source specifically designed to treat pre-cancerous skin lesions, Actinic Keratosis, a disease that develops as a result of cumulative photodamage caused by exposure of too much sunlight. Biofrontera believes that it is critical to advise patients that AK can potentially progress into squamous cell carcinoma and  effective treatment is crucial in slowing disease progression.

Since its U.S. launch in 2016, Biofrontera, Inc., has also been investing in efforts to improve treatment possibilities for non-melanoma skin cancer with the help of PDT. This cutting-edge technology allows for the effective and selective elimination of sun-induced skin damage while maintaining healthy skin and offering good cosmetic results.

PDT allows for the long-term elimination of malignant skin cells in a targeted way. Biofrontera’s medication for PDT and the specific LED light source to target the affected cells was approved in Europe and USA only after an extensive and long-term study. It stabilized the substance deployed and improved its transport through the skin to the target site (the cells that had undergone a malignant transformation) using a proprietary dosage form.

Biofrontera Inc.’s aim is to be a valued partner in the dermatological community, providing patients and healthcare providers with unsurpassed medicines and services. Commitment, quality, and client attention are three of the company’s central tenets.

As one of the most forward-thinking companies, Biofrontera Inc. brings unparalleled therapies and service to patients and healthcare providers in the dermatology community by focusing on innovative therapy options that enable dermatology healthcare professionals to help improve the lives of their patients. It considers itself to be at the frontier of PDT treatments, with the objective of making PDT the standard of care in the field of dermatology.

“We are committed to partnering with our industry to bring innovative, unparalleled advancement to the dermatology community.  Our PDT treatment offers competitive advantages for both patients and practitioners.  Our recent IPO will allow us to continue investment in the dermatology community, and assisting doctors in all aspects of performing PDT in their offices, including patient information, reimbursement or medical information as key areas of focus,” says Erica Monaco, CEO of Biofrontera Inc.

Biofrontera Inc. has been listed on Nasdaq since October 2021. Thanks to the IPO and subsequent private placement, it is well-positioned for future expansion as a leading, broadly acting dermatology company. It also has full access to the opportunities the US capital market provides.

In order to guarantee that Biofrontera understands its clients’ challenges and develops strategies to assist them in overcoming those very challenges, the company is collecting feedback from the industry as it establishes its commercial presence. Furthermore, the outcomes of its licensing partner’s clinical trials, as well as the post-market research Biofrontera supports, have each demonstrated its product’s enormous potential. Biofrontera’s core values focus on quality and commitment which is demonstrated through their emphasis on assisting doctors encompassing all elements of PDT in their clinics, including patient information, reimbursement, and medical information.

PDT optimization will continue to be an important aspect of Biofrontera’s research in the future. With the support of its industry expertise, Biofrontera intends to gradually improve on its existing knowledge in the field of photodynamic treatment and expand the indications for its product. By establishing a strong link between the two, the enterprise hopes to make Biofrontera Inc. the face of photodynamic therapy.

Today, Biofrontera provides effective and innovative solutions that are adapted to the specific needs of patients. More than anything, the company is dedicated to bringing new ideas to the dermatology community. Biofrontera aspires to be a major player in dermatology in the next ten years. It is already a trusted, consultative partner for healthcare practitioners and patients across the U.S., providing outstanding full-service customer support. Biofrontera’s mission is to help PDT achieve its full potential and support this therapy in attaining global success.